Home » Stocks » BSX

Boston Scientific Corporation (BSX)

Stock Price: $34.41 USD 0.60 (1.77%)
Updated December 4, 4:00 PM EST - Market closed
After-hours: $34.34 -0.07 (-0.20%) Dec 4, 6:26 PM

BSX Stock Price Chart

Key Info

Market Cap 49.27B
Revenue (ttm) 10.11B
Net Income (ttm) 3.69B
Shares Out 1.43B
EPS (ttm) 2.61
PE Ratio 13.21
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 4
Last Price $34.41
Previous Close $33.81
Change ($) 0.60
Change (%) 1.77%
Day's Open 33.80
Day's Range 33.57 - 34.42
Day's Volume 26,382,462
52-Week Range 25.83 - 45.71

BSX Stock News

InvestorPlace - 1 day ago

Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.

Other stocks mentioned: AMGN, BIIB
Zacks Investment Research - 2 days ago

BTG's core Interventional Medicines business now is expected to exceed Boston Scientific's (BSX) original goal of $175 million in synergies.

Market Watch - 3 days ago

Boston Scientific Corp. said Tuesday it is selling its BTG Specialty Pharmaceuticals business to Stark International Lux S.A.R.L. and SERB SAS, both affiliates of specialty pharma group SERB, ...

PRNewsWire - 3 days ago

MARLBOROUGH, Mass., Dec. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement with Stark International Lux S.A.R.L....

Zacks Investment Research - 1 week ago

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 week ago

NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX).   ...

Forbes - 1 week ago

Here is an interesting fact. While most stocks have been climbing, Boston Scientific's stock is doing something different.

PRNewsWire - 1 week ago

MARLBOROUGH, Mass., Nov. 23, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 2020 Evercore ISI HealthCONx Conference on December 1. Mike Mahon...

PRNewsWire - 2 weeks ago

NEW YORK, Nov. 20, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating potential claims against Boston Scientific Corporation (NYSE: BSX) ("BSX" or the ...

Forbes - 2 weeks ago

Despite a 47% rise since the March lows, at the current price of around $38 per share we believe Boston Scientific stock, has more room for growth in the near term. BSX stock has rallied from ...

Market Watch - 2 weeks ago

Boston Scientific Corp. said Tuesday it has launched a voluntary recall of unused stock of its LOTUS Edge Aortic Valve System due to "complexities" relating to the product delivery system. "Th...

Zacks Investment Research - 3 weeks ago

Boston Scientific (BSX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Forbes - 3 weeks ago

Stocks are likely to consolidate or trend slightly higher.

Other stocks mentioned: BA
PRNewsWire - 4 weeks ago

MARLBOROUGH, Mass., Nov. 5, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences. On November 12, 2020, Meghan Scanlon, ...

PRNewsWire - 1 month ago

MARLBOROUGH, Mass., Nov. 2, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the Ranger™ Drug-Coated Balloon, de...

PRNewsWire - 1 month ago

MARLBOROUGH, Mass., Oct. 29, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the CHAMPION-AF clinical trial to evaluate the safety and efficacy of the WATCHMAN FLX...

Seeking Alpha - 1 month ago

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 1 month ago

Boston Scientific's (BSX) Q3 earnings and revenues decline year over year but improve sequentially.

Zacks Investment Research - 1 month ago

Boston Scientific (BSX) delivered earnings and revenue surprises of 48.00% and 5.58%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the s...

PRNewsWire - 1 month ago

MARLBOROUGH, Mass., Oct. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated sales of $2.659 billion during the third quarter of 2020. This represents a decline of (1....

Market Watch - 1 month ago

Boston Scientific Corp. posted a better-than-expected third-quarter adjusted profit and sales that topped estimates. The Marlborough, Mass.

Zacks Investment Research - 1 month ago

In Q3, Medical Product stocks are expected to have gained from gradual lifting of restrictions in many states and regions. However, international sales might have been dampened.

Other stocks mentioned: CERN, LVGO, PEN
Zacks Investment Research - 1 month ago

Boston Scientific's (BSX) Q3 sales are expected to have benefited from growing demand for less-deferrable procedures across most of the segments.

Zacks Investment Research - 1 month ago

Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 month ago

Within Endoscopy, Boston Scientific (BSX) believes that business recovery started since June.

24/7 Wall Street - 1 month ago

While technology has been the engine that has driven stock market performance for some time now, increasingly we are seeing a seismic shift to health care among many portfolio managers, and wi...

Other stocks mentioned: ABBV, MDT, SYK, ZBH
PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Oct. 1, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast an investor update at the virtual 2020 Transcatheter Cardiovascular Therapeutics (TCT) o...

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Sept. 30, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced the European launch of the WaveWriter Alpha™ portfolio of Spinal Cord Stimulator (SCS) Systems....

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Sept. 28, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has initiated a controlled launch of the ACURATE neo2™ Aortic Valve System in Eu...

Zacks Investment Research - 2 months ago

Boston Scientific (BSX) aims to provide a comprehensive portfolio of electrophysiology products and services via the latest investment agreement.

Forbes - 2 months ago

We believe Boston Scientific stock could see an upside of over 10% in the near term. BSX stock trades at $39 currently and it has lost 15% of its value so far this year.

PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Sept. 21, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse...

Zacks Investment Research - 2 months ago

Boston Scientific (BSX) aims to optimize therapy outcomes via the fourth-generation Vercise Genus DBS System's post-regulatory clearance in Europe.

CNBC Television - 2 months ago

Final Trades: Seattle Genetics, Booking Holdings, Boston Scientific & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: BKNG, SGEN, VIAC, XLI
PRNewsWire - 2 months ago

MARLBOROUGH, Mass., Sept. 9, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced it has received CE Mark and initiated a limited market release of the fourth generation Ve...

Zacks Investment Research - 3 months ago

Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.

PRNewsWire - 3 months ago

MARLBOROUGH, Mass., Sept. 3, 2020 /PRNewswire/ -- Boston Scientific (NYSE: BSX) announced that the U.S.

Investors Business Daily - 3 months ago

Intuitive Surgical, Edwards Lifesciences, Boston Scientific, Novocure and Guardant Health are top medical stocks that may thrive as coronavirus cases fall.

Other stocks mentioned: EW, ISRG, GH, NVCR
Zacks Investment Research - 3 months ago

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 3 months ago

MARLBOROUGH, Mass., Aug. 26, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming virtual investor conferences.

Forbes - 3 months ago

Though Boston Scientific (NYSE: BSX) has seen its stock rise by over 50% since the March 23 lows, it is still down by 13% year-to-date. The stock now trades at over 39x projected 2020 earnings...

Zacks Investment Research - 3 months ago

Boston Scientific's (BSX) business arm's MMA for Voraxaze (glucarpidase) accepted by EMA for review.

PRNewsWire - 3 months ago

LONDON, Aug. 17, 2020 /PRNewswire/ -- BTG Specialty Pharmaceuticals, a division of Boston Scientific (NYSE:BSX), today announced the European Medicines Agency (EMA) has accepted for review a M...

Seeking Alpha - 3 months ago

Boston Scientific: This Healthcare Technology Company Is Poised To Thrive

The Motley Fool - 3 months ago

New products mean solid revenue may be ahead for these companies.

Other stocks mentioned: ABBV, AMGN
Seeking Alpha - 4 months ago

Boston Scientific Corporation (BSX) CEO Michael Mahoney on Q2 2020 Results - Earnings Call Transcript

CNBC Television - 4 months ago

Final Trades: Akamai, General Motors, Boston Scientific & more

The "Halftime Report" traders give their top picks to watch for the second half.

Other stocks mentioned: AKAM, GM, NDAQ
Zacks Investment Research - 4 months ago

This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.

Zacks Investment Research - 4 months ago

Boston Scientific (BSX) delivered earnings and revenue surprises of 300.00% and 22.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Investors Business Daily - 4 months ago

Boston Scientific earnings were positive on adjusted basis. Analysts expected the medical device giant to report a loss.

About BSX

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]

Industry
Medical Devices
IPO Date
May 18, 1992
CEO
Michael Mahoney
Employees
36,000
Stock Exchange
NYSE
Ticker Symbol
BSX
Full Company Profile

Financial Performance

In 2019, BSX's revenue was $10.74 billion, an increase of 9.28% compared to the previous year's $9.82 billion. Earnings were $4.70 billion, an increase of 181.27%.

Financial Statements

Analyst Forecasts

According to 27 analysts, the average rating for BSX stock is "Buy." The 12-month stock price forecast is 43.46, which is an increase of 26.30% from the latest price.

Price Target
$43.46
(26.30% upside)
Analyst Consensus: Buy